VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

VolitionRx eliminates a $7.5 million convertible note early, aiming to reduce potential dilution and improve its overall financial position.

Rhea-AI Summary

VolitionRx (VNRX) has fully prepaid in cash a senior secured convertible promissory note with an original principal of $7.5 million issued to Lind Global Asset Management XII LLC.

The note, dated May 20, 2025 and originally maturing May 20, 2027, is now fully satisfied and all related obligations are discharged. Volition states that this early repayment, more than eight months before the scheduled maturity, removes potential equity dilution linked to the note. A separate senior secured convertible promissory note dated January 7, 2026, with an original principal of $2.4 million, remains outstanding in the amount of $2,041,667.

Positive

• $7.5 million senior secured convertible note fully prepaid in cash
• Early repayment made over eight months before scheduled May 20, 2027 maturity
• Remaining Lind note balance reduced to $2,041,667 from $2.4 million original principal

Negative

• None.

Argus 15 min delay

+5.09% vs previous close $0.33 last price 6.1x rel. volume Open Argus

Details

Market reaction after debt repayment: VNRX +5.09%

+1.4% Peak in 0 min

$0.31 $0.34 Day Range

$6.16M Market Cap

Following this news, VNRX has gained 5.09%, reflecting a notable positive market reaction. Argus tracked a peak move of +1.4% during the session. Our momentum scanner has triggered 5 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.33. Trading volume is exceptionally heavy at 6.1x the average, suggesting very strong buying interest.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

10,006,360 shares were registered for resale under the active S-3/A, while this announcement retired...

Analysis

10,006,360 shares were registered for resale under the active S-3/A, while this announcement retired one Lind note in cash; the filing stated Volition would receive no resale proceeds from those transactions.

Key Figures

Note principal prepaid: $7,500,000 Remaining note balance: $2,041,667 Remaining note original principal: $2,400,000 +1 more

Note principal prepaid

$7,500,000

Senior secured convertible promissory note dated May 20, 2025; prepaid in full

Remaining note balance

$2,041,667

January 7, 2026 senior secured convertible promissory note

Remaining note original principal

$2,400,000

January 7, 2026 note issued to Lind

Prepayment timing

More than eight months ahead

Relative to the originally scheduled maturity date

Key Terms

senior secured convertible promissory note, convertible promissory note

2 terms

senior secured convertible promissory note financial

"the outstanding balance on its senior secured convertible promissory note"

A senior secured convertible promissory note is a formal IOU a company issues that is backed by specific assets (secured), given higher priority for repayment than other debts (senior), and can be exchanged for company shares instead of cash (convertible). For investors this means the loan is safer than unsecured debt because it has collateral and repayment priority, but it also carries the potential for dilution if the lender converts the note into equity — like holding a mortgage-backed IOU that can later be swapped for ownership stakes.

convertible promissory note financial

"The senior secured convertible promissory note, dated January 7, 2026"

A convertible promissory note is a loan a company takes now that can later be turned into shares instead of being repaid in cash. Think of it as lending money with the option to accept ownership in the business down the road; that matters to investors because it affects who gets paid first, how much ownership existing shareholders keep, and the company’s future valuation and cash needs. Terms such as conversion price, interest and maturity determine the financial impact.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Reduces Equity Overhang

HENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory note, dated May 20, 2025, in the original principal amount of $7,500,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind"). Following the pre-payment, all obligations under the Note have been satisfied. The senior secured convertible promissory note, dated January 7, 2026, in the original principal amount of $2,400,000, also issued to Lind, remains outstanding in the amount of $2,041,667.

Cameron Reynolds, Chief Executive Officer, Volition, commented:

"We are very pleased to be in a position to retire the outstanding balance of this note to Lind, more than eight months ahead of our originally scheduled maturity date.

"By prepaying the balance in cash, we prevent further potential dilution to our stockholders associated with the note.

"We are continuing to execute against our plan to improve Volition's financial position and further debt and expense reduction remains a top priority moving forward as we seek to maximize stockholder value."

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements reflect the current belief and expectations of management and relate to, among other topics, statements regarding the pre-payment of the Note and future reductions of debt and expenses. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Volition believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are subject to risks and uncertainties that may cause Volition's actual activities or results to differ materially from those indicated or implied by any forward- looking statement, including, without limitation, due to risks and uncertainties related to risks disclosed in the documents Volition files from time to time with the SEC, including Volition's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

 

View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-announces-pre-payment-in-full-of-7-5-million-senior-secured-convertible-promissory-note-due-may-20--2027--302877586.html

SOURCE VolitionRx Limited

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What type of debt did VolitionRx repay and who was the lender?

VolitionRx repaid in full a senior secured convertible promissory note, originally $7,500,000 in principal, that had been issued to Lind Global Asset Management XII LLC.

How much debt to Lind remains outstanding after this prepayment?

A separate senior secured convertible promissory note dated January 7, 2026, also issued to Lind, remains outstanding in the amount of $2,041,667, from an original principal of $2,400,000.

Why does VolitionRx say it chose to prepay the $7.5 million note?

The company states that by prepaying the balance in cash, it prevents further potential dilution to stockholders associated with the convertible note and continues its plan to improve its financial position, with further debt and expense reduction described as a top priority.